Cencora, Inc. (NYSE:COR) Shares Purchased by City State Bank

City State Bank boosted its stake in Cencora, Inc. (NYSE:COR) by 19.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 618 shares of the company’s stock after acquiring an additional 100 shares during the period. City State Bank’s holdings in Cencora were worth $139,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Concord Wealth Partners purchased a new stake in Cencora in the 3rd quarter valued at approximately $30,000. SYSTM Wealth Solutions LLC purchased a new stake in Cencora in the 2nd quarter valued at approximately $36,000. Ashton Thomas Securities LLC purchased a new stake in Cencora in the 3rd quarter valued at approximately $41,000. Fairscale Capital LLC purchased a new stake in Cencora in the 2nd quarter valued at approximately $54,000. Finally, Modus Advisors LLC purchased a new stake in Cencora in the 4th quarter valued at approximately $54,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Price Performance

COR stock opened at $236.10 on Tuesday. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $253.27. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The stock’s 50 day moving average price is $237.82 and its 200 day moving average price is $233.54. The firm has a market cap of $45.63 billion, a P/E ratio of 31.44, a PEG ratio of 1.54 and a beta of 0.49.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were paid a $0.55 dividend. The ex-dividend date was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.93%. This is a positive change from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio is presently 29.29%.

Wall Street Analysts Forecast Growth

COR has been the topic of a number of analyst reports. StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Bank of America reaffirmed a “neutral” rating and issued a $245.00 price objective (down previously from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Wells Fargo & Company decreased their price target on Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a research note on Friday, December 13th. Mizuho assumed coverage on Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price target on the stock. Finally, Evercore ISI boosted their price target on Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $275.60.

Insider Activity at Cencora

In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of the business’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the completion of the transaction, the chairman now directly owns 326,557 shares in the company, valued at approximately $79,670,111.29. The trade was a 13.28 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the transaction, the executive vice president now owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 94,696 shares of company stock valued at $22,862,734. 15.80% of the stock is owned by corporate insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.